Overview

LAM Pilot Study With Imatinib Mesylate

Status:
Completed
Trial end date:
2019-03-07
Target enrollment:
Participant gender:
Summary
This is a phase 1 clinical trial comparing imatinib mesylate to placebo for individuals with lymphangioleiomyomatosis (LAM).
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Medical University of South Carolina
Collaborator:
Columbia University
Treatments:
Imatinib Mesylate
Sirolimus